drugset

drugset / Trial / NCT00991419

To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

NCT00991419 ↗

Phase 2 Completed 25 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to compare PET measurements of fibrillar amyloid burden using \[18F\]AZD4694.

Timeline

Start: 2010-02
Primary completion: 2011-08
Completion: 2011-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[18F]NAV4694	Diagnostic / imaging agent	—	—

Indications